TAILORx: Trial Assigning Individualized Options for Treatment (Rx)

Clinical Breast Cancer

Volumn 7, Issue 4, 2006, Pages 347-350

  Sparano, Joseph A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Oncotype DX assay; Recurrence score; REMARK guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ACCESS TO INFORMATION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG CHOICE; GENETIC ANALYSIS; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INDIVIDUALIZATION; INFORMED CONSENT; INTERNET; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL INFORMATION SYSTEM; NORTH AMERICA; ONLINE SYSTEM; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; REGISTRATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR VOLUME; UNITED STATES;

EID: 33750895236     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.051     Document Type: Article

References (14)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4(suppl 1): S1-26.
3. Harlan LC, Clegg LX, Abrams J, et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006; 24:872-877.
4. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 62-66.
5. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23:2716-2725.
6. Whelan T, Levine M, Willan A, et al. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA 2004; 292:435-441.
7. Whelan TJ, Loprinzi C. Physician/patient decision aids for adjuvant therapy. J Clin Oncol 2005; 23:1627-1630.
8. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 2001; 146-152.
9. McShane LM, Altman DG, Sauerbrei W, et al. Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK). Eur J Cancer 2005; 41:1690-1696.
10. Sparano JA, Fazzari MJ, Childs G. Clinical application of molecular profiling in breast cancer. Future Oncol 2005; 1:485-496.
11. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826.
12. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8:1125.
13. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-3734.
14. Mamounas E, T. G., Bryant J, Paik S, Shak S, et al. Association between the 21-gene recurrence score assay (RS) and risk of loco-regional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2005; 94(suppl 1):S16 (Abstract #29).